Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Trading 10-23 10:17:31 EDT

395.62

-17.19

-4.16%

High410.41	Low395.50	Vol1.48M
Open410.41	D1 Closing412.82	Amplitude3.61%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O25.91M	T/O Rate--	Tradable Shares0.00
P/B2.558253	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":395.6242,"timestamp":1792765050817,"preClose":412.81503,"halted":0,"volume":1477875,"delay":0,"changeRate":-0.041643,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-17.190826,"latestTime":"10-23 10:17:31 EDT","open":410.41483,"high":410.41483,"low":395.5037,"amount":25912940.314758,"amplitude":0.036121,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792785600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.558253,"peRate":-9.223068,"turnoverRate":0.003371,"increases":0,"decrements":4,"flats":0,"marketCap":8923743424,"floatMarketCap":8416721520},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2677472029","title":"Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2677472029","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677472029?lang=en_us&edition=fundamental","pubTime":"2026-10-23 16:33","pubTimestamp":1792744419,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics appointed Dr. Jing L. Marantz as Executive Vice President and Chief Medical Officer in October 2026, putting her in charge of translational, development, regulatory and medical affairs across the pipeline.\nHer track record steering rare disease programs from trials through FDA, EMA and Japanese regulators gives Intellia a leader experienced with complex global approvals and multi-asset portfolios.\nWe will now look at how Intellia Therapeutics's investment narrative...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/learn-why-the-bull-case-for-intellia-therapeutics-stock-coul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RGLO","VOTE","BK4139","FEBU","LU1861559042.SGD","DECU","GXDW","NTLA","BK4535","LU1861558580.USD","JOYT","BK4588","PMDE","BK4556","VGFPF","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677988841","title":"Crispr Therapeutics Files Initial Beneficial Ownership Statement for CFO Andrew Jacob Silver","url":"https://stock-news.laohu8.com/highlight/detail?id=2677988841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677988841?lang=en_us&edition=fundamental","pubTime":"2026-10-22 05:36","pubTimestamp":1792618595,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Files Initial Beneficial Ownership Statement for CFO Andrew Jacob SilverCRISPR Therapeutics Chief Financial Officer Andrew Jacob Silver filed an initial statement of beneficial own","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL4fVlsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4588","BK4139","ARKG","LU1861559042.SGD","CRSP","LU1861558580.USD","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676444636","title":"CRISPR Therapeutics Appoints Andrew Silver as New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2676444636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676444636?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:27","pubTimestamp":1792441672,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On October 19, 2026, CRISPR Therapeutics AG promoted Andrew J. Silver, previously...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-appoints-andrew-silver-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-appoints-andrew-silver-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SImain","SETM","LU1861558580.USD","BK4611","SYNB","BK4585","BK4588","CRSP","BK4556","LU1861559042.SGD","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676368756","title":"Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2676368756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676368756?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:16","pubTimestamp":1792440965,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics (CRSP) announced that its CFO, Raju Prasad will be stepping down from the company to pursue external opportunities, and A.J. Si...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-cfo-raju-prasad-to-step-down-a-j-silver-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-cfo-raju-prasad-to-step-down-a-j-silver-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ARKG","BK4556","LU1861558580.USD","BK4588","CRSP","LU1861559042.SGD","SETM","BK4611","CFO","BK4007","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676635286","title":"Crispr Therapeutics Names A.J. Silver CFO, Succeeding Raju Prasad","url":"https://stock-news.laohu8.com/highlight/detail?id=2676635286","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676635286?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:11","pubTimestamp":1792440711,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Names A.J. Silver CFO, Succeeding Raju PrasadCRISPR Therapeutics appointed its senior vice president of finance as chief financial officer, effective today.Outgoing CFO Raju Prasad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL5QBcdq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","IE00B3QW5Z07.USD","CRSP","BK4112","IE00BKPKM429.USD","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","LU1861558580.USD","BCDF","SG9999014039.USD","BK4611","BK4556","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","LU1861559042.SGD","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4139","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676635128","title":"Press Release: Crispr Therapeutics Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2676635128","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676635128?lang=en_us&edition=fundamental","pubTime":"2026-10-20 04:05","pubTimestamp":1792440300,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4604","TM","BK4611","R","BK4232","BK4099","BK4555","LENZ","BK4585","LU1861558580.USD","BK4539","SYNB","CRSP","ARKG","03160","BK4022","BK4556","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676483549","title":"Amprius, Viking, Regeneron, Ionis, Crispr Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2676483549","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676483549?lang=en_us&edition=fundamental","pubTime":"2026-10-17 17:02","pubTimestamp":1792227724,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($AMPX) ), ( ($VKTX) ), ( ($REGN) ), ( ($IONS) ) and ( ($CRSP) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/amprius-viking-regeneron-ionis-crispr-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/amprius-viking-regeneron-ionis-crispr-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ARKG","BK4611","BK4585","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4556","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676819510","title":"Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2676819510","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676819510?lang=en_us&edition=fundamental","pubTime":"2026-10-17 08:10","pubTimestamp":1792195821,"startTime":"0","endTime":"0","summary":"Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common SharesBeam Therapeutics CEO and director John M. Evans sold 50,000 common shares on October 15-16, 2026.Sales totaled 25,000","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261017:nNDLbSCV6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","BK4139","BK4611","LU1861559042.SGD","BK4556","LU1861558580.USD","BK4585","BEAM","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676512458","title":"Crispr Therapeutics Director Simeon George Reports Disposal of Common Shares Worth $720,373.362","url":"https://stock-news.laohu8.com/highlight/detail?id=2676512458","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676512458?lang=en_us&edition=fundamental","pubTime":"2026-10-17 05:46","pubTimestamp":1792187191,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Director Simeon George Reports Disposal of Common Shares Worth $720,373.362CRISPR Therapeutics director Simeon George sold 14,514 Common Shares on October 14, 2026, at $49.633 per ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDLfdXT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crispr Therapeutics Director Simeon George Reports Disposal of Common Shares Worth $720,373.362","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4556","ARKG","CRSP","LU1861559042.SGD","BK4139","LU1861558580.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675328324","title":"Wedbush Remains a Buy on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675328324","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675328324?lang=en_us&edition=fundamental","pubTime":"2026-10-14 22:05","pubTimestamp":1791986726,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Beam Therapeutics today and set a price target of $65.00. In a report released today, Canaccord Genuity ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","LU1861558580.USD","BK4139","BK4505","LU1861559042.SGD","BEAM","BK4611","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675346450","title":"Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675346450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675346450?lang=en_us&edition=fundamental","pubTime":"2026-10-14 19:20","pubTimestamp":1791976828,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edgewise Therapeutics (EWTX), Beam Therapeutics (BEA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-edgewise-therapeutics-ewtx-beam-therapeutics-beam-and-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-edgewise-therapeutics-ewtx-beam-therapeutics-beam-and-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","BK4137","MDGL","BK4585","XLV","LU1861558580.USD","LU2324357040.USD","HCSG","LABU","BK4556","BK4539","LU0128526141.USD","BK4535","BK4505","LU1861559042.SGD","BK4588","BK4007","BK4611","BEAM","XBI","LU0029874061.USD","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675359113","title":"Intellia Therapeutics appoints Jing Marantz as chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675359113","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675359113?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:36","pubTimestamp":1791891365,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced the appointment of Jing Marantz as executive VP and chief medical officer, effective October 26. Marantz wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-appoints-jing-marantz-as-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-appoints-jing-marantz-as-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","LU1861558580.USD","BK4139","LU1861559042.SGD","NTLA","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356044","title":"Intellia Therapeutics Appoints Jing L. Marantz, M.d., Ph.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675356044?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUAHZS6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","LU1861559042.SGD","NTLA","BK4588","BK4556","BK4535","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675535606","title":"Press Release: Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675535606","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675535606?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NTLA","BK4022","LU1861559042.SGD","BK4139","BK4232","BK4585","IDNA","R","LU1861558580.USD","BK4535","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675550733","title":"Beam Therapeutics Reports Initial Phase 1/2 Data for BEAM-301 in Glycogen Storage Disease Type Ia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2675550733","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675550733?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:05","pubTimestamp":1791889545,"startTime":"0","endTime":"0","summary":"Beam Therapeutics reports initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia trialBeam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL17C6Bx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BEAM","BK4535","LU2210149790.SGD","IE00BQXX3C00.GBP","BK4139","IE00BN0W2W23.USD","BK4112","BCDF","IE00B3QW5Z07.USD","BK4505","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","LU1861558580.USD","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4611","LU1861559042.SGD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883808","title":"Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883808","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883808?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:35","pubTimestamp":1791495338,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics General Counsel James R. Kasinger disposes of 1,990 common shares worth $119,481.19James R. Kasinger, general counsel and secretary, exercised stock options for 1,990 common shares","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL65MQgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ARKG","BK4611","BK4585","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4556","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673077189","title":"CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673077189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673077189?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:30","pubTimestamp":1791462600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310, its investigational CRISPR/Cas9","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377269/0/en/crispr-therapeutics-to-present-late-breaking-data-at-the-american-heart-association-aha-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","BK4139","BK4117","LU1861559042.SGD","AFG","SYNB","LU1861558580.USD","AGT","ARKG","BK4588","CRSP","BK4556","BK4611","BK4585","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673607171","title":"Editas wins approval to launch EDIT-401 Strive trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673607171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673607171?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458930,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Editas Medicine ( ($EDIT) ). On October 8, 2026, Editas Medicine said it had secured approval in Australia to b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-wins-approval-to-launch-edit-401-strive-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-wins-approval-to-launch-edit-401-strive-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673939071","title":"Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673939071","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673939071?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458907,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) received approval in Australia to initiate the phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia, the company said Thursday","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYAU.AU","GIVE.AU","EDIT","EIGA.AU","IOZ.AU","SLF.AU","IIGF.AU","BEAR.AU","VAP.AU","QRE.AU","DACE.AU","QFN.AU","XAO.AU","GEAR.AU","STW.AU","BBOZ.AU","BK4139","OZR.AU","IISV.AU","BK4556","IMLC.AU","E200.AU","VAS.AU","XKO.AU","XJO.AU","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071338","title":"Editas Medicine receives approval to initiate clinical trial of EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071338?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457602,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","BK4556","MEDX","BK4139","NVIB","GDOC","EDIT","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction